An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
Jennifer M. Kwon(University of Wisconsin–Madison), Nancy L. Kuntz(Lurie Children's Hospital), Silvia Bader‐Weder(Roche (Switzerland)), Vamshi K. Rao(Northwestern University), Travis L. Dickendesher, Jennifer L. Hansen(Bridge University), Aravindhan Veerapandiyan(Arkansas Children's Hospital), Beverly Assman, Kathryn J. Swoboda(Massachusetts General Hospital), Kapil Arya(Arkansas Children's Hospital), Ying Yan(Zhejiang Financial College), Helen Lin, Cory Sieburg(University of Wisconsin–Madison), H. Phan(Rare Disease Therapeutics (United States))
Cited by 36
Related Papers
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Mutations in the skeletal muscle α-actin gene in patients with actin myopathy and nemaline myopathy
|Nature Genetics|1999|401
TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum
|Nature Genetics|2011|381
CNS aquaporin-4 autoimmunity in children
|Neurology|2008|323
<i><scp>LTBP4</scp></i> genotype predicts age of ambulatory loss in duchenne muscular dystrophy
|Annals of Neurology|2012|242